Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
BMC Infect Dis ; 23(1): 70, 2023 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-36747151

RESUMO

BACKGROUND: Serum lipids variations are closely related to the sepsis progression; however, their value for patients with pyogenic liver abscesses (PLA) has rarely been studied. We investigated the serum lipid level variations in patients with PLA and its predictive value to the disease. METHODS: The study included 328 patients with PLA hospitalized in the First Affiliated Hospital of Nanjing Medical University from January 2017 to December 2021; 35 (10.67%) in the severe group (SG) and 293 (89.33%) in the non-severe group (nSG). Their clinical records were analyzed retrospectively, and dynamic curves were drawn to clarify the changes in different indicators during the course of the disease. RESULTS: High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a) (Lp(a)) in the SG were significantly lower than those in nSG (P < 0.001). Total cholesterol (TC) at baseline (OR = 0.184, P < 0.001) was an independent risk factor for severe patients and had the highest predictive value, with an area under the curve of 0.859 and a cut-off value of 2.70 mmol/L (sensitivity = 94.3%, specificity = 63.5%). For patients who met the criteria for drainage surgery, TC, HDL-C and LDL-C levels continued to decrease with antibiotic therapy alone before drainage and began to increase after the surgery. CONCLUSIONS: Low TC level on admission is an independent risk factor for the progression of severe illness in PLA patients, with the highest predictive value surpassing other routine clinical indices. Abscess drainage should be performed as soon as possible for patients whose TC continues to decline after medical treatment.


Assuntos
Colesterol , Abscesso Hepático Piogênico , Humanos , Estudos Retrospectivos , LDL-Colesterol , Triglicerídeos , Prognóstico , Relevância Clínica , HDL-Colesterol , Poliésteres
2.
Pharmazie ; 73(2): 70-75, 2018 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-29442007

RESUMO

The objective of this study was to prepare a new compound fenbendazole tablet containing 29.7 % fenbendazole, 1.50 % praziquantel and 0.059 % ivermectin for oral administration. The tablets were successfully prepared using mannitol as filler agent, polyvinyl polypyrrolidone as disintegrant, 5 % povidone (PVAK30) as a binder agent and magnesium stearate as lubricant. The appearance, hardness, fragility, time limit of disintegration and fenbendazole dissolution at 45 min all met the technical standards of the Ministry of Agriculture for the People's Republic of China. We used high performance liquid chromatography and electrospray-mass spectrometry for drug detection. Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively. The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively. This study enriches the pharmacokinetic data of compound fenbendazole tablets using dogs as a model system. The new tablet formulation was assimilated quickly and systemically and this study will be beneficial for the clinical application of parasite treatments in dogs.


Assuntos
Antinematódeos/administração & dosagem , Antinematódeos/farmacocinética , Fenbendazol/administração & dosagem , Fenbendazol/farmacocinética , Administração Oral , Animais , Cromatografia Líquida de Alta Pressão , Cães , Composição de Medicamentos , Excipientes , Meia-Vida , Manitol , Povidona , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray , Ácidos Esteáricos , Comprimidos
3.
Biomed Pharmacother ; 173: 116309, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38479180

RESUMO

As the leading killer of life and health, stroke leads to limb paralysis, speech disorder, dysphagia, cognitive impairment, mental depression and other symptoms, which entail a significant financial burden to society and families. At present, physiology, clinical medicine, engineering, and materials science, advanced biomaterials standing on the foothold of these interdisciplinary disciplines provide new opportunities and possibilities for the cure of stroke. Among them, hydrogels have been endowed with more possibilities. It is well-known that hydrogels can be employed as potential biosensors, medication delivery vectors, and cell transporters or matrices in tissue engineering in tissue engineering, and outperform many traditional therapeutic drugs, surgery, and materials. Therefore, hydrogels become a popular scaffolding treatment option for stroke. Diverse synthetic hydrogels were designed according to different pathophysiological mechanisms from the recently reported literature will be thoroughly explored. The biological uses of several types of hydrogels will be highlighted, including pro-angiogenesis, pro-neurogenesis, anti-oxidation, anti-inflammation and anti-apoptosis. Finally, considerations and challenges of using hydrogels in the treatment of stroke are summarized.


Assuntos
Técnicas Biossensoriais , Acidente Vascular Cerebral , Humanos , Hidrogéis/uso terapêutico , Materiais Biocompatíveis , Engenharia Tecidual , Acidente Vascular Cerebral/tratamento farmacológico
4.
Carbohydr Polym ; 296: 119969, 2022 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-36088008

RESUMO

Metal-organic frameworks (MOFs) and their derived powder catalysts are prone to agglomerate and difficult to recycle in water, thus resulting in their low utilization and secondary pollution in water treatment. Herein, a composite aerogel (CoFe0.8@NCNT@CA) loaded with bimetallic MOF-derived carbon nanotubes on cellulose aerogel was developed for activating peroxymonosulfate (PMS) to degrade tetracycline (TC). The CoFe0.8@NCNT@CA/PMS system exhibits an excellent TC removal rate (97.1 % TC removal within 20 min). The outstanding performance of the composite catalyst is closely related to the synergistic effect of bimetallic catalytic sites, graphitic N structure, and porous network. Interestingly, carbon nanotubes and cellulose in the composite catalyst form a semi-coated porous structure, which can effectively enhance the adhesion of carbon nanotubes and expose abundant active sites while ensuring mass transfer. This study provides a strategy for synthesizing novel composite aerogel with an excellent structure and physicochemical properties for water treatment.


Assuntos
Celulose , Nanotubos de Carbono , Catálise , Peróxidos/química
5.
Drug Deliv ; 25(1): 909-915, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29649952

RESUMO

The aim of this study was to prepare cefquinome-loaded polylactic acid microspheres and to evaluate their in vitro and in vivo characteristics and pharmacodynamics for the therapy of pneumonia in a rat model. Microspheres were prepared using a 0.7 mm two-fluid nozzle spray drier in one step resulting in spherical and smooth microspheres of uniform size (9.8 ± 3.6 µm). The encapsulation efficiency and drug loading of cefquinome were 91.6 ± 2.6% and 18.7 ± 1.2%, respectively. In vitro release of cefquinome from the microspheres was sustained for 36 h. Cefquinome-loaded polylactic acid microspheres as a drug delivery system was successful for clearing experimental Klebsiella pneumonia lung infections. A decrease in inflammatory cells and an inhibition of inflammatory cytokines TNF-α, IL-1ß and IL-8 after microspheres treatment was found. Changes in cytokine levels and types are secondary manifestations of drug bactericidal effects. Rats were considered to be microbiologically cured because the bacterial load was less than 100 CFU/g. These results also indicated that the spray-drying method of loading therapeutic drug into polylactic acid microspheres is a straightforward and safe method for lung-targeting therapy in animals.


Assuntos
Antibacterianos/administração & dosagem , Cefalosporinas/administração & dosagem , Portadores de Fármacos , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Pneumonia Bacteriana/tratamento farmacológico , Poliésteres/química , Animais , Antibacterianos/química , Carga Bacteriana , Cefalosporinas/química , Modelos Animais de Doenças , Composição de Medicamentos , Liberação Controlada de Fármacos , Interações Hospedeiro-Patógeno , Mediadores da Inflamação/sangue , Interleucina-1beta/sangue , Interleucina-8/sangue , Infecções por Klebsiella/sangue , Infecções por Klebsiella/microbiologia , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/patogenicidade , Pulmão/microbiologia , Pulmão/patologia , Masculino , Microesferas , Tamanho da Partícula , Pneumonia Bacteriana/sangue , Pneumonia Bacteriana/microbiologia , Pneumonia Bacteriana/patologia , Ratos Wistar , Propriedades de Superfície , Tecnologia Farmacêutica/métodos , Fatores de Tempo , Fator de Necrose Tumoral alfa/sangue
6.
Curr Gene Ther ; 10(2): 156-66, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20353385

RESUMO

Acute liver failure (ALF) is a life-threatening medical emergency and occurs when the liver rapidly loses its function within a short period. ALF can develop secondary to a variety of causes. Currently, the orthotopic liver transplantation is the "Gold Standard" therapy for the disease. However, due to the limited availability of donor organs and rapid progression of the disease, the mortality of ALF remains high. Therefore, it is imperative to develop novel therapeutic reagents for ALF. Gene therapy by delivering a target gene to the patients appears to be a promising approach for the treatment of ALF. Here, we review the recent advance of gene therapy for ALF, focusing on the three technical elements, animal models, vehicles for gene delivery and technique for gene delivery, which are important for the success of gene therapy as well as the potential targets used for the treatment of ALF.


Assuntos
Terapia Genética/métodos , Falência Hepática Aguda/terapia , Animais , DNA/administração & dosagem , Modelos Animais de Doenças , Técnicas de Transferência de Genes , Genes , Vetores Genéticos , Humanos , Lipossomos , Falência Hepática Aguda/genética , Nanopartículas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA